Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
AssigneeSK Bioscience Co., Ltd.
InventorsYun Hee KIM, Yong Wook PARK, Dong Soo HAM, Hwan Ui JUNG, Hun KIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of preparing an influenza working virus seed stock, a method of increasing infectivity of an influenza working virus seed stock, a method of preparing an influenza vaccine using the seed stock, an influenza vaccine prepared by the method, and an influenza working virus seed stock having increased infectivity.
Claims14
A method of preparing an influenza working virus seed stock, comprising infecting a cell line adapted to serum-free culture and suspension culture with an influenza vaccine virus, culturing the infected cell line, and further passaging the virus culture in the same cell line wherein a culture with a dilution factor where the highest cell viability is obtained is selected from cultures with different dilution factors used for viral infection, provided that when the hemagglutination assay (HA) titers (except for 0) of two or more cultures are different by 4 times or more, a culture with a dilution factor where the highest HA titer is obtained is selected and used for the subsequent passage.
A method of increasing the infectivity of an influenza working virus seed stock, comprising infecting a cell line adapted to serum-free culture and suspension culture with an influenza vaccine virus, culturing the infected cell line, and further passaging the virus culture in the same cell line to prepare an influenza working virus seed stock wherein a culture with a dilution factor where the highest cell viability is obtained is selected from cultures with different dilution factors used for viral infection, provided that when the hemagglutination assay (HA) titers (except for 0) of two or more cultures are different by 4 times or more, a culture with a dilution factor where the highest HA titer is obtained is selected and used for the subsequent passage.
Dependencies are inferred from the claim text.